Newsroom

Sorted by: Latest

-

Exstent Appoints Matt Thompson as CEO to Drive Global Growth in Personalised Aortic Support

LONDON--(BUSINESS WIRE)--Exstent, a UK-based medical device company, developing personalised external aortic support to preserve the native aorta, today announced the appointment of Matt Thompson as Chief Executive Officer to lead its next phase of global growth. Matt brings more than two decades of combined clinical and commercial leadership to Exstent. He previously held leadership roles including President and CEO at Endologix, guiding the company through transformation, portfolio growth, an...
-

Verition Fund Management LLC UK Regulatory Announcement: Form 8.3

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Verition Fund Management LLC (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be n...
-

Pershing Square Holdings, Ltd. UK Regulatory Announcement: Transaction in Own Shares

LONDON--(BUSINESS WIRE)--  Pershing Square Holdings, Ltd. Announces Transactions in Own Shares - 11 November 2025 Pershing Square Holdings, Ltd. (LN:PSH) (LN:PSHD) (“PSH”) today announced that it has purchased, through PSH’s agent, Jefferies International Limited (“Jefferies”), the following number of PSH’s Public Shares of no par value (ISIN Code: GG00BPFJTF46) (the "Shares"): Total Buyback   Ticker/s: PSH (LSE); PSHD (LSE) Date of Purchase: 11 November 2025 Number of Public Shares Purchased:...
-

Verition Fund Management LLC UK Regulatory Announcement: Form 8.3 - Amendment

LONDON--(BUSINESS WIRE)--  AMENDMENT: This form replaces our last form released on 10th November 2025 at 17:26 GMT. The amendment relates to Section 2(a). FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Verition Fund Management LLC (b) Owner or controller of interests and short positions disclosed, if different from 1(...
-

Hoffmann Green Signs a Distribution Partnership with Matériaux Travaux Publics, a Key Player in the Building Materials Trade in the South-West

CHAILLÉ-SOUS-LES-ORMEAUX, France--(BUSINESS WIRE)--Regulatory News: Hoffmann Green Cement Technologies (ISIN: FR0013451044, Ticker: ALHGR) (“Hoffmann Green Cement” or the “Company”), an industrial player committed to the decarbonation of the construction sector that designs and markets innovative cold produced, clinker-free cements, announces the signing of a partnership with Matériaux Travaux Publics (MTP), a leading distributor of construction materials for public work companies in the Aquita...
-

Hoffmann Green signe un partenariat de distribution avec Matériaux Travaux Publics, acteur majeur du négoce de matériaux du Sud-Ouest

CHAILLÉ-SOUS-LES-ORMEAUX, France--(BUSINESS WIRE)--Regulatory News: Hoffmann Green Cement Technologies (ISIN : FR0013451044, Mnémo : ALHGR) (« Hoffmann Green Cement » ou la « Société »), acteur industriel engagé dans la décarbonation du secteur de la construction qui conçoit et commercialise des ciments innovants sans clinker, annonce la signature d’un partenariat avec Matériaux Travaux Publics (MTP), acteur de référence du négoce de matériaux destinés aux entreprises de travaux publics en Aqui...
-

NFL Biosciences Presents the Agenda for Results Expected by Regulatory Agencies and Potential Pharmaceutical Partners

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: NFL Biosciences SA (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company developing innovative botanical drugs for the treatment of addiction, today presents the communication agenda for the initial results of the work requested by regulatory agencies and awaited by pharmaceutical companies interested in licensing NFL-101, its first-in-class drug candidate for smoking cessation. Regulatory agencies have emphasized the...
-

NFL Biosciences présente le calendrier de résultats attendus par les agences réglementaires et les partenaires pharmaceutiques potentiels

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News : NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), société biopharmaceutique développant des médicaments botaniques innovants pour le traitement des addictions, présente le calendrier de communication des premiers résultats de travaux demandés par les agences réglementaires et attendus par les laboratoires pharmaceutiques intéressés par une prise de licence de NFL-101, son candidat médicament first in class dans l’indication d...
-

Resecurity Appoints Ammar Jaffri as Senior Advisor for Pakistan

LOS ANGELES--(BUSINESS WIRE)--Resecurity (USA), a California-based cybersecurity company renowned for its intelligence-driven solutions protecting critical infrastructure and global enterprises, has appointed Ammar Jaffri, a distinguished cybersecurity expert and former Former Additional Director General FIA (Federal Investigation Agency), Government of Pakistan, as Senior Advisor for Pakistan. This strategic appointment to Advisory Board underscores Resecurity’s commitment to expanding its foo...
-

ADOCIA annonce le dépôt de brevet d’une nouvelle plateforme de peptides à action prolongée pour le diabète et l’obésité - AdoXLong™ - et fait le point sur sa plateforme BioChaperone®

LYON, France--(BUSINESS WIRE)--Regulatory News : Adocia (Euronext Paris : FR0011184241 – ADOC), société biopharmaceutique au stade clinique spécialisée dans la recherche et le développement de solutions thérapeutiques innovantes pour le traitement du diabète et de l’obésité, annonce ce jour la soumission d’une demande de brevet sur une nouvelle plateforme de peptides à action prolongée, et deux études de faisabilité utilisant sa technologie BioChaperone® avec deux sociétés pharmaceutiques non d...